Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy
Audrey M Sigmund,* Kieran D Sahasrabudhe,* Bhavana Bhatnagar Division of Hematology, Department of Internal Medicine, The Ohio State University and the Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA*These authors contributed equally to this workCorrespondence: Bhavana Bha...
Guardado en:
Autores principales: | Sigmund AM, Sahasrabudhe KD, Bhatnagar B |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b11495eba1d74f478741d26b3469e17b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
por: Bhutani D, et al.
Publicado: (2017) -
IDH1-mutated relapsed or refractory AML: current challenges and future prospects
por: Megías-Vericat JE, et al.
Publicado: (2019) -
Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
por: Karantanos T, et al.
Publicado: (2017) -
Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
por: Hagop M. Kantarjian, et al.
Publicado: (2021) -
Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
por: Gupta VA, et al.
Publicado: (2013)